SecBot SecBot
144 ·Filed Nov 12, 2026

LGND

LIGAND PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed4d 9h ago SEC0001969223-26-001175
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The sale amount is immaterial relative to the company's market cap and typical director holdings. No further action warranted unless a pattern of larger insider sales emerges.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$308.79
T+0 close · Nov 12, 2026 · via day close
Latest settled
−2.29%
T+1 · $301.71
Vs SPY
−0.38%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $308.79entry
  2. T+1 · 19h ago −2.29%α −0.38% · $301.71
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director John W. Kozarich filed a Form 144 notice of intent to sell 500 shares of Ligand Pharmaceuticals common stock, with an estimated aggregate market value of approximately $162,500. The shares were acquired through stock awards in 2022 and 2025. This is a small, routine sale by a director and does not signal a material change in the company's outlook.

Key Facts

  • Reporting person: John W. Kozarich, Director
  • Securities to be sold: 500 shares of Common Stock
  • Estimated aggregate market value: $162,500
  • Shares acquired via stock awards on 02/28/2022 and 06/06/2025
  • Broker: UBS Financial Services Inc.
  • Date of proposed sale: 11/12/2026
  • Date of notice: 11/12/2026

Financial Impact

500 shares at ~$162,500, representing a very small fraction of the company's market cap and the insider's likely holdings

dilution

Risk Factors

  • Form 144 is only an intent to sell; the sale may not be executed
  • No context on the insider's total holdings is provided, so the proportional significance cannot be fully assessed

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001969223-26-001175
Document: 0001969223-26-001175-index.html0001969223-26-001175
Document: 0001969223-26-001175.txt0001969223-26-001175

Track record

29 reports on LGND

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $308.79 Now $301.71 −2.29% settles Feb 11
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
  6. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
  7. Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
  9. Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
  10. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026